Guggenheim Securities, the investment banking arm of Guggenheim Partners, has formed a strategic alliance with Australia’s ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

You still can’t buy a World Series championship in baseball, as hard as teams like the Dodgers and Mets and Yankees and ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Japanese art star Takashi Murakami is teaming up with Major League Baseball for its upcoming Tokyo games in a new ...

Looking for something to do in New York? Catch the superstar Diana Ross at the Kings Theater, learn all about crankies, or ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...